Nordson NDSN
Industrials · Industrial - Machinery · Synthos Deep Dive · 2026-07-03
The Overview
Nordson makes the precise nozzles, pumps and dispensing machines that squirt exactly the right amount of glue, coating, or fluid onto things — the adhesive in your diaper, the sealant in your phone, the coating on a medical tube, the solder on a circuit board. It is a quiet, boring, extremely profitable niche leader: it keeps about 55 cents of gross profit on every sales dollar and sells mostly to factories that keep coming back for parts and refills.
The catch: it's a good company at a fair-to-full price. You're paying about $25 for every $1 of next year's expected earnings, and the business only grows sales in the low-to-mid single digits. So there isn't much bargain here. Our verdict is Watch — a great business to own, but wait for a cheaper entry rather than pay up today.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). Solid balance sheet and a stock that moves roughly with the market — but it carries some debt from acquisitions, and its sales rise and fall with the factory-spending cycle.
- Growth Quality 6/10 (good, not great). Wonderful profit margins and returns, but the top line grows slowly.
- Exponential Potential 3/10 (low). This is a steady grinder, not a rocket. Don't expect it to double quickly.
The one big worry: Nordson's sales depend on factories deciding to buy equipment, which is cyclical — and the one expert voice we have flags that its appetite for bigger, debt-funded acquisitions could dull the disciplined "flywheel" that made it great.
Putting a number on it: our fair-value estimate is $300 against a current price of $324.59 — consistent with our call to stay away or wait for a better setup.
Our summary metrics
Beta ~1.0, net-debt/EBITDA ~2.1×, 25× forward EPS on ~6% revenue growth — full but not extreme; cyclicality is the flag.
Elite margins (55% GM, 31% EBITDA, ~14% ROCE) but low-single-digit organic revenue growth; EPS CAGR mid-teens on buybacks/mix.
Mature niche-industrial compounder, revenue barely accelerating; $16B cap in mature end-markets caps the multibagger.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature niche-industrial compounder, revenue barely accelerating; $16B cap in mature end-markets caps the multibagger.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $324 (high $345 / low $300; 13 Buy · 8 Hold · 0 Sell) — context, not our anchor |
| Valuation | 31× TTM EPS · 25× FY26E · 23× FY27E · 22× FY28E · EV/S 6.2× · EV/EBITDA 19.8× |
| Technicals | Mild uptrend — $290, −4.7% off 52-wk high, above 50/200-DMA, RSI 55, +31.7% 12-mo (SPY +20.6%) |
| Conviction | Low — 0 net-bullish voices; the only KB claim is cautionary (Business Breakdowns); this is a fundamentals/quant call |
| Position sizing | Satellite quality-industrial, ~1–2% if bought — and only on a pullback |
What the experts actually said 1 traceable claims on NDSN · showing the highest-conviction voices
“Strong industrial competitor but moving into larger levered acquisitions, creating risk it loses the disciplined flywheel focus Graco keeps.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $324.59, 7% above the 50-day average ($303), 17% above the 200-day average ($277) — an uptrend. 3% below the 52-week high of $335, 47% above the 52-week low of $222.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $324.59 is currently inside the band (band $294–$340).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 60.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.98, positive momentum.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = NDSN · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Nordson Corporation (NASDAQ: NDSN) is a ~115-year-old Westlake, Ohio precision-technology company that engineers, manufactures and markets systems to dispense, apply and control adhesives, coatings, polymers, sealants, biomaterials and other fluids. The economic engine is a classic razor-and-blade industrial model: sell durable dispensing equipment, then earn a long, high-margin annuity on consumable nozzles, pumps, filters, tips and parts. Fiscal year ends October 31 (note: NDSN reports on an Oct fiscal year, so "FY25" = year ended 2025-10-31).
Revenue mix — by segment (FY2024, from filings; the three-segment structure adopted after the FY24 reorg):
- Industrial Precision Solutions (IPS): $1.484B (~55%) — adhesive dispensing for disposables/packaging, polymer processing, coatings, and precision agriculture.
- Medical and Fluid Solutions (MFS): $695M (~26%) — medical tubing, balloons, cannulae, fluid components; a stickier, higher-margin franchise.
- Advanced Technology Solutions (ATS): $510M (~19%) — electronics dispense, test & inspection (x-ray, acoustic microscopy) for semiconductor/PCB.
Revenue mix — by geography (FY2024, from filings): Americas ex-US $1.179B, Asia-Pacific ex-Japan $785M, Europe $726M (the current FMP taxonomy folds the US into "Americas"; historically the US ran ~30–35% of sales). The base is genuinely global and diversified across consumer non-durable, medical, electronics and industrial end-markets — which dampens any single end-market shock but ties the whole to the global industrial capex cycle.
The strategic frame management pushes is the "Ascend Strategy" / NBS Next growth framework — a division-led, close-to-the-customer operating model layered on top of a steady bolt-on M&A cadence (most recently CapstanAG in precision agriculture, March 2026).
2. The expert thesis (traceable)
There is effectively no bullish expert coverage of NDSN in the Synthos KB. total_claims = 1, net_bullish_voices = 0. The single claim is cautionary, so this verdict is fundamentals- and quant-driven, not conviction-driven — and we say so plainly.
- The one voice — Business Breakdowns (bearish/cautionary, conviction 55, skill 1.0, dated 2024-10-25) (
business_breakdowns-Q2sjfW9URTE:a8d4e2675b): "Strong industrial competitor but moving into larger levered acquisitions, creating risk it loses the disciplined flywheel focus Graco keeps." The thesis is not that Nordson is a bad business — it explicitly calls it a "strong industrial competitor" — but that its drift toward bigger, debt-financed deals (the Medical/CyberOptics/ARAG-era acquisitions) risks eroding the disciplined, high-return capital-allocation flywheel that peers like Graco protect.
Honest composite note. With one cautionary claim and zero net-bullish voices, the KB tilts negative, but at low breadth and moderate skill it is not decisive on its own. We treat it as a red-flag to verify against the numbers (see §9 capital allocation and §5 leverage) rather than a standalone sell signal. The verdict rests on the fundamentals and valuation below.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Beta ~0.98 and interest coverage 6.7× are steadying, but net-debt/EBITDA ~2.1× carries real leverage and the top line is cyclical (order/backlog driven). 25× forward EPS on ~6% growth leaves modest cushion. |
| Growth Quality | 6 · Good | Elite margins (55% GM, 31% EBITDA, 18% net) and healthy returns (ROE 17%, ROCE 14%), but organic revenue growth is only low-to-mid single digit; EPS CAGR mid-teens leans on buybacks, mix and M&A, not volume. |
| Exponential Potential | 3 · Low | Mature niche-industrial franchise; revenue barely accelerating (backlog +18% is the one green shoot). At $16B in mature end-markets, the multibagger math isn't there. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Electronics/semi and medical demand accelerate; backlog +18% converts; adjusted EPS beats to ~$12.5 (FY27E); the market keeps a premium ~29× for the quality/margins. | ~$360 (+24%) |
| Base (our anchor) | Guidance roughly holds — FY26 adj-EPS lands mid-guide ~$11.5, FY27E ~$12.6; a durable high-margin compounder earns a ~24× forward multiple. | ~$300 (+3%) |
| Bear | Industrial-capex cycle rolls over; orders/backlog soften; a levered acquisition disappoints (the KB's worry). FY27E adj-EPS misses to ~$11; multiple de-rates to ~20×. | ~$225 (−22%) |
Synthos fair value = the base case, ~$300 (+3%), with the full $225–$360 span as the honest range. Our anchor sits below the Street's $324 consensus — we give less credit to multiple expansion on a mid-single-digit grower. That +3% base upside is the core of the Watch call: nothing is broken, but the price already reflects the quality. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). NDSN is a genuine compounder with low exponential potential:
- Forward growth: revenue CAGR FY25→FY28E ~5.5% ($2.79B → $3.28B); adjusted-EPS CAGR ~mid-teens ($8.51 dil FY25 → ~$13.4 FY28E consensus) — but note the EPS growth is amplified by buybacks (share count down ~57.6M → ~55.8M) and mix, not by unit-volume acceleration.
- Acceleration (the 2nd derivative) is roughly flat-to-slightly-positive: organic sales grew +7% in Q2'26 with backlog +18% YoY — a real, encouraging re-acceleration off the 2023–24 industrial soft patch, but off a low base and still cyclical. This is not a structural inflection; it's a cyclical up-leg.
- Room to run: the end-markets (adhesives, coatings, electronics dispense, medical fluid components) are mature, niche and already well-penetrated by Nordson. At $16B market cap in these markets, the law of large numbers plus modest TAM growth caps the multibagger: NDSN compounds low-teens total return; it does not 3–5× quickly.
- Reinvestment runway: modest, high-return capex (~2% of revenue) plus bolt-on M&A — the reinvestment story is disciplined and profitable, which is exactly why it's a compounder, but it's not a growth-reinvestment flywheel that re-rates the multiple.
Exponential Potential: Low (3/10). Own it, if at all, for durable mid-teens EPS compounding and best-in-class margins — not for a fast multibagger. A $2B version of this business growing 15%+ organically would score 7–8; this mature $16B compounder does not.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 (ended 2025-10-31) $2.792B, +3.8% (FY24 $2.690B, +2.3% on FY23 $2.629B). Steady but slow; the 2023–24 stretch was a cyclical trough. Q2'26 sales $741M, +8.5% YoY (organic +7%) — the cyclical up-leg is showing.
- Quarterly trajectory: Q1'26 $669M → Q2'26 $741M; H1'26 sales $1.410B vs $1.298B H1'25 (+8.6%). Re-acceleration confirmed in the latest prints.
- Margins (best-in-class for the peer set): gross 55.1% TTM, EBITDA 31.4% TTM, operating ~26%, net 18.2% TTM. Segment EBITDA margins (Q2'26): IPS 35%, MFS 37%, ATS 27%.
- Earnings: net income $484.5M FY25 (EPS dil $8.51); TTM net income per share ~$9.47. Q2'26 GAAP EPS $2.09 was depressed by a one-time non-cash pension-annuitization charge and minority-investment loss; adjusted EPS $2.86 (+18% YoY) is the cleaner read.
- Cash flow: operating CF $719M FY25, capex ~−$58M (a light 1.7% of sales), FCF $661M — a ~24% FCF margin and >136% FCF/net-income conversion. This is the quality tell: Nordson turns earnings into cash exceptionally well.
- Balance sheet: total debt $2.16B, net debt $2.05B, net-debt/EBITDA ~2.06× — investment-grade (letter rating B+ / overall score 3) and comfortably serviced (interest coverage 6.7×), but a real leverage load that has crept up with the M&A cadence.
6. Valuation — priced in or room?
NDSN is not cheap and not egregious — it's fair-to-full. Trailing: 31× EPS, 6.2× sales, 19.8× EV/EBITDA, 5.1× book. On live consensus the forward P/E is 25× (FY26E) → 23× (FY27E) → 22× (FY28E) — the multiple compresses only slowly because EPS growth is only mid-teens and decelerating. A PEG-style read (fwd P/E ÷ EPS growth) sits around ~1.5–1.6×, i.e. you're paying a premium multiple for a modest grower, justified by the margin/cash-conversion quality but leaving little valuation cushion. Street targets (context): consensus $324, high $345, low $300 — notably the Street low ($300) sits above today's $290 and roughly at our base FV, telling you the sell-side sees limited downside but also limited upside. Our ~$300 base is a touch below consensus because we won't underwrite multiple expansion on a ~6% revenue grower. Verdict: a quality-industrial-at-a-full-price hold, not a value buy.
7. Technicals (from the tech block)
- Trend: mildly up. $290.38 sits above the 50-DMA ($286.66) and 200-DMA ($262.42), and the 50 is above the 200 (golden-cross posture). MACD +3.57 (mildly positive).
- Location: −4.7% off the 52-week high ($304.64), +38.8% off the 52-week low ($209.25) — mid-to-upper range, shallow max drawdown (−4.7% from peak).
- Momentum: RSI(14) 54.8 — neutral, neither overbought nor oversold; no stretched-entry signal, but also no oversold bargain setup.
- Relative strength: NDSN +31.7% 12-mo vs SPY +20.6% (outperforming the market) but +8.7% 3-mo vs QQQ +22.0% (lagging tech recently). A steady, market-beating industrial, not a momentum leader.
- Read: technicals are constructive but not urgent — an orderly uptrend with room before overbought, but no oversold entry. Consistent with the Watch stance: a pullback toward the rising 200-DMA (~$262) would be a materially better risk/reward entry than chasing near $290.
8. Moat & competitive position
Nordson's moat is a razor-and-blade installed base: high-precision equipment engineered into a customer's production line, followed by a long, sticky, high-margin consumables/parts annuity. Switching costs are real (requalifying a dispensing system on a live production line is costly and risky), applications engineering is deep, and the direct-sales model keeps Nordson close to the customer — together these produce the 55% gross / 31% EBITDA margins and ~14% ROCE that define the franchise. The structural risks are cyclicality (capital-equipment orders swing with industrial capex) and acquisition-integration/leverage (the KB's specific worry, §2).
Peer set (market cap, from FMP): the closest quality comps are Graco $12.5B (the KB's benchmark for disciplined capital allocation) and IDEX $16.6B; the broader industrial-machinery cohort includes ITT $16.7B, Donaldson $10.3B, Lincoln Electric $14.2B, Crane $12.6B, Watsco $16.7B, WESCO $15.0B, CNH $13.3B, ATI $25.7B. Within this group NDSN carries among the highest margins and one of the richer multiples — the premium is earned on quality but leaves less room for error than cheaper peers.
9. Management, capital allocation & guidance
- Capital allocation: a disciplined mix — FY25 returned ~$306M in buybacks and ~$179M in dividends while paying down ~$230M of debt, all funded by $661M FCF. The dividend is well-covered (payout ~34%) and Nordson is a long-standing dividend grower. The open question the KB raises is deal discipline: the shift toward larger, levered acquisitions (Medical, CyberOptics, ARAG, and now bolt-ons like CapstanAG) is what pushed net-debt/EBITDA to ~2.1×. The numbers so far show the flywheel intact (FCF conversion >130%, ROCE ~14%), but this is the metric to watch.
- Insider activity: the sampled window (through 2026-06-02) shows routine award/grant and tax-withholding ("F-InKind") activity plus one gift and one option exercise — normal compensation mechanics, no cluster of alarming open-market discretionary selling.
- Management's own guidance (the earnings-release track — half-weighted, management's self-interested words): the SEC 8-K (Item 2.02) for Q2'26 (filed 2026-05-20) is a genuine earnings release and Nordson raised full-year FY26 guidance: sales $2.930–$3.010B and adjusted EPS $11.30–$11.80, with Q3'26 sales $760–$790M and adjusted EPS $2.95–$3.15. Management (CEO Sundaram Nagarajan) cites backlog +18% YoY and broad-based order momentum across all three segments as the basis. Treat this as management's own self-interested framing (half-weight) — but the raise plus the backlog data point is a real, checkable positive that supports the cyclical up-leg thesis.
10. Catalysts & what to watch
- Next earnings: 2026-08-19 (Q3'26; Street EPS $3.05, management adj-EPS guide $2.95–$3.15, sales guide $760–$790M). The key line: organic order entry and backlog (does the +18% hold or start converting/fading?).
- Backlog conversion: whether the +18% backlog turns into sustained organic revenue growth vs. a one-time restock.
- Electronics/semi cycle (ATS): the swing segment — semiconductor/PCB dispense and test demand is the most cyclical and the biggest upside/downside lever.
- M&A cadence & leverage: any new large levered deal (the KB's flagged risk) — watch net-debt/EBITDA and whether ROIC on deals holds.
- Medical (MFS) organic growth: the stickiest, highest-margin franchise; sustained mid-single-digit-plus organic growth here supports the premium multiple.
Thesis tripwires (what would change the call): backlog rolling over two quarters running; net-debt/EBITDA pushing toward 3× on a new deal; organic revenue turning negative; or the stock re-rating below ~20× forward (which would flip Watch → Buy on valuation).
11. Key risks
- Cyclicality (structural): revenue is order/backlog-driven capital-equipment demand tied to global industrial capex — it troughed in 2023–24 and can again.
- Levered-M&A drift (the KB's one worry):
business_breakdowns-Q2sjfW9URTE:a8d4e2675b— bigger, debt-funded deals risk eroding the disciplined flywheel; net-debt/EBITDA is already ~2.1×. - Valuation / de-rating: 25× forward on ~6% revenue growth leaves little cushion if growth or margins disappoint.
- End-market concentration within segments: electronics/semi (ATS) is volatile; a downturn there hits growth and mix.
- FX & trade policy: ~65%+ of sales are non-US; currency swings and tariff/trade-policy shifts move reported results (management flags this explicitly in its own risk language).
12. Verdict, position sizing & monitoring
Watch. Nordson is a genuinely high-quality precision-industrial compounder — 55% gross margin, 31% EBITDA margin, >130% FCF conversion, backlog +18%, and management raising FY26 guidance. But quality is not the same as opportunity: at ~25× forward EPS on mid-single-digit organic revenue growth, the stock already reflects the franchise, our base-case fair value (~$300) is only ~3% above spot and below the Street's $324, and the sole expert voice in the KB is cautionary on capital-allocation drift. There is no margin of safety and no conviction breadth to override the valuation. That's a Watch, not a Buy.
- Sizing: if owned, satellite quality-industrial, ~1–2% — and ideally initiated on a pullback toward the 200-DMA (~$262) or a re-rating below ~20× forward, not chased at $290.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $290.38.
- Single biggest risk: the industrial-capex cycle plus levered-M&A appetite — the one worry the KB's cautionary voice names.
Provenance & disclosures
- Traceability: 1 KB claim, breadth 0 net-bullish voices, the single claim cautionary (Business Breakdowns, skill 1.0, dated 2024-10-25) — reconciled to a real
claim_id(business_breakdowns-Q2sjfW9URTE:a8d4e2675b). This is a fundamentals/quant-driven verdict; there is no bullish expert conviction to cite, and we say so. Fabricated conviction is structurally impossible (claim-ID reconciliation). - Data as-of: fundamentals 2026-04-30 (Q2'26; Oct fiscal year) · estimates & prices 2026-07-02/03 · the single expert claim dated 2024-10-25. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: the FY26 guidance in §9 is management's own self-interested earnings-release language (SEC 8-K, 2026-05-20), half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").